Jon DiVincenzo has served as Executive Vice President and President, Central Laboratories and International at Labcorp since 2023.
Jon has been with Labcorp since 2017, most recently serving as head of Clinical Trials Testing Solutions (CTTS), with oversight of Central Laboratory Services (CLS), BioAnalytical and CMC laboratory services.
Under his leadership, Labcorp has made significant advancements in its global footprint to support growth and innovation. The company opened new anatomic pathology facilities in the United States and abroad, and completed the expansion of anatomic pathology, genomics and microbiology labs in Singapore, Shanghai and Japan. In addition, Jon led Labcorp’s efforts to automate its kit assembly line in Mechelen, Belgium and the construction of a new kit production facility in Suzhou, China.
Before joining Labcorp, he served as President of the Environmental Health division of PerkinElmer. He has held numerous leadership roles throughout his career including President and Chief Executive Officer at Enzymatics and President of the Bioscience Division of EMD Millipore, a subsidiary of Merk KGaA.
Jon holds a bachelor’s degree in mechanical engineering from Northeastern University.
What is Jonathan P. DiVincenzo's net worth?
The estimated net worth of Jonathan P. DiVincenzo is at least $889.09 thousand as of February 21st, 2024. Mr. DiVincenzo owns 3,401 shares of Labcorp stock worth more than $889,089 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. DiVincenzo may own. Learn More about Jonathan P. DiVincenzo's net worth.
How do I contact Jonathan P. DiVincenzo?
Has Jonathan P. DiVincenzo been buying or selling shares of Labcorp?
Jonathan P. DiVincenzo has not been actively trading shares of Labcorp within the last three months. Most recently, Jonathan P. Divincenzo sold 500 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $215.49, for a transaction totalling $107,745.00. Following the completion of the sale, the executive vice president now directly owns 3,401 shares of the company's stock, valued at $732,881.49. Learn More on Jonathan P. DiVincenzo's trading history.
Who are Labcorp's active insiders?
Labcorp's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Richelle Parham (Director), Adam Schechter (Chairman, President, and CEO), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Labcorp's active insiders.
Are insiders buying or selling shares of Labcorp?
During the last year, insiders at the medical research company sold shares 19 times. They sold a total of 54,892 shares worth more than $14,048,330.71. The most recent insider tranaction occured on November, 11th when CEO Adam H Schechter sold 5,745 shares worth more than $1,509,498.75. Insiders at Labcorp own 0.8% of the company.
Learn More about insider trades at Labcorp. Information on this page was last updated on 11/11/2025.
